SCHEMBL18855751

SCHEMBL18855751

Cc1ccc([S+]([O-])n2ccc3c2ncc2nncn23)cc1

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18855535 0.85 DRD1 (0.31) —
SCHEMBL1935366 0.73 L3MBTL1 (0.47) —
SCHEMBL18855569 0.72 SMN1; SMN2 (0.33) SMN1; SMN2
SCHEMBL18855573 0.72 AURKA (0.44) —
SCHEMBL18855950 0.67 — —
SCHEMBL18855935 0.67 ABL1 (0.37) SMN1; SMN2
SCHEMBL24243000 0.66 — —
SCHEMBL18855873 0.64 — —
SCHEMBL24243062 0.63 IKBKB (0.30) —
SCHEMBL21470789 0.62 MGAM (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3950692-A1 NOVEL TRICYCLIC COMPOUNDS AbbVie Inc. (US) 2022-02-09 — — EP disclosed
EP-2506716-B1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC (US) 2017-05-17 — — EP disclosed
Send feedback